The role of inflammation in coronary artery disease has been recognized for years, but recent developments have sparked renewed interest. The FDA’s 2023 approval of colchicine, the first drug specifically aimed at treating coronary inflammation, has led many cardiology experts to explore how this and other medications could change the treatment landscape for cardiovascular disease.
In an interview with Cardiovascular Business, Dr. Deepak L. Bhatt, director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, shared his insights on this trend at TCT 2024.
He has dedicated years to studying inflammation and its impact on heart health.
Dr. Bhatt highlighted that coronary inflammation is now seen as a significant contributor to myocardial infarctions, or heart attacks. “The data supporting inflammation as a risk factor for cardiovascular disease is quite strong,” he stated. He also drew parallels between the current challenges of targeting inflammation and past difficulties in addressing low HDL cholesterol levels.
As research continues to evolve, experts like Dr. Bhatt are optimistic that new treatments targeting inflammation will lead to better outcomes for patients with cardiovascular disease.
Related topics:
- New Prosthetic Valve Set to Transform Treatment for Common Heart Condition
- American Heart Association Launches $75 Million Fund to Support Women’s Health Initiatives
- AI-Powered ECG Model Predicts Heart Disease Risk with Precision